OS Therapies (NYSEAMERICAN:OSTX) Downgraded to Strong Sell Rating by Zacks Research

Key Points

• Zacks Research downgraded OS Therapies (OSTX) from a "hold" to a "strong sell"; analyst opinions are mixed (two buys, one sell) with a consensus rating of "Hold" and a consensus target price of $18.50 while D. Boral Capital maintains a $20 target.
• The stock opened at $1.70 with a market cap of $67.2M, trades near its 50- and 200-day moving averages, and the company reported negative EPS (‑$0.41 last quarter) with analysts forecasting about ‑$0.54 for the fiscal year.
• OS Therapies is a clinical-stage biopharmaceutical developing osteosarcoma therapies (OST-HER2 and OST-tADC), and several institutional investors including Two Sigma and CM Management have recently built or increased positions.

OS Therapies (NYSEAMERICAN:OSTX - Get Free Report) was downgraded by Zacks Research from a "hold" rating to a "strong sell" rating in a report issued on Wednesday,Zacks.com reports.

Separately, D. Boral Capital reissued a "buy" rating and issued a $20.00 target price on shares of OS Therapies in a research note on Thursday, April 30th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $18.50.

OS Therapies Price Performance

OSTX opened at $1.70 on Wednesday. The company's 50 day simple moving average is $1.47 and its two-hundred day simple moving average is $1.55. OS Therapies has a 1-year low of $1.15 and a 1-year high of $2.57. The firm has a market capitalization of $67.20 million, a price-to-earnings ratio of -1.72 and a beta of -1.34.

OS Therapies (NYSEAMERICAN:OSTX - Get Free Report) last released its earnings results on Tuesday, March 31st. The company reported ($0.41) earnings per share for the quarter. On average, equities analysts anticipate that OS Therapies will post -0.54 earnings per share for the current fiscal year.

Institutional Trading of OS Therapies

A number of hedge funds and other institutional investors have recently made changes to their positions in OSTX. XTX Topco Ltd acquired a new stake in shares of OS Therapies during the 2nd quarter worth approximately $63,000. Bridgeway Capital Management LLC acquired a new stake in shares of OS Therapies during the 2nd quarter worth approximately $47,000. Ground Swell Capital LLC acquired a new stake in shares of OS Therapies during the 3rd quarter worth approximately $40,000. CM Management LLC increased its holdings in shares of OS Therapies by 6.7% during the 3rd quarter. CM Management LLC now owns 400,000 shares of the company's stock worth $784,000 after buying an additional 25,000 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new stake in shares of OS Therapies during the 3rd quarter worth approximately $169,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.